Tag: Gene Therapies

Bioassay Services – A Prerequisite for the Cell and Gene Therapy Development Over the past few years, investigational new drug (IND) filings by cell and gene therapy companies have significantly increased. In fact, from year 2016 to 2020 more than 300 IND filing for cell and gene therapy product have been recorded, indicating that several

Gene therapy companies have emerged as the savior in offering sophisticated products to treat patients with defective genes and chronic diseases. There are two types of gene therapies on the basis of targeted gene location: germline gene therapy and somatic gene therapy. These therapies are implemented to treat several diseases, such as hemophilia, Parkinson’s, Alzheimer’s,

The first gene therapy, Gendicine®, was only approved in 2003 in China; since then, the domain has evolved significantly. The ‘Gene Therapy Market (2nd Edition), 2018-2030’ report provides an extensive study on the current market landscape of gene therapies, with a prime focus on gene augmentation based therapies and oncolytic viral therapies, featuring an elaborate discussion on